ArticleDiabetes care1997
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.
Article in Diabetes care, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
Open the trial in the graphProspective Randomized Controlled Trial on the Effect of Gastric Bypass and Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI > 35 vs. Medical Therapy
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 270 citations in OpenAlex.
- Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes care · 2009 · on this mapGuideline
- Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.BMJ (Clinical research ed.) · 2025Trial
- Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.Scientific reports · 2018Trial
- Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial.Scientific reports · 2017Trial
- Trial
- Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections.Journal of diabetes research · 2016Trial
- Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.Journal of diabetes research · 2016Trial
- Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2014Trial
- Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.Diabetes technology & therapeutics · 2013Trial
- Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.Acta diabetologica · 2013Trial
- β-cell function preservation after 3.5 years of intensive diabetes therapy.Diabetes care · 2012Trial
- Early basal insulin therapy decreases new-onset diabetes after renal transplantation.Journal of the American Society of Nephrology : JASN · 2012Trial
- Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.Diabetes technology & therapeutics · 2012Trial
- Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?Diabetes care · 2009Trial
- The effects of combined insulin and metformin therapy in obese patients with diabetes mellitus type 2 in the early stage of the disease.Bosnian journal of basic medical sciences · 2006Trial
- Intensive intravenous infusion of insulin in diabetic cats.Journal of veterinary internal medicineTrial
- The role of the beta cell in type 2 diabetes: new findings from the last 5 years.Diabetologia · 2025Review
- Evaluating the Effectiveness of Insulin Plus Oral Medications Versus Oral Anti-Diabetes Therapy Alone in Patients With Newly Diagnosed Type 2 Diabetes With Very High hbA1c and Acute Coronary Syndrome.Endocrinology, diabetes & metabolism · 2025Observational
- Reversal of high-glucose-induced transcriptional and epigenetic memories through NRF2 pathway activation.Life science alliance · 2024Article
- Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveType 2 diabetes is a slowly progressive disease, in which the gradual deterioration of glucose tolerance is associated with the progressive decrease in beta-cell function. Hyperglycemia per se has deleterious effects on both beta-cell function and insulin action, which are partially reversible by the short-term control of blood glucose levels. We hypothesized that the induction of euglycemia, using intensive insulin therapy at the time of clinical diagnosis, could lead to a significant improvement in insulin secretion and action and thus alter the clinical course of the disease. RESEARCH DESIGN AND
methodsThirteen newly diagnosed diet-unresponsive type 2 diabetic patients were treated with continuous subcutaneous insulin infusion (CSII) for 2 weeks and followed longitudinally while being treated with diet alone.
resultsFour patients were considered therapeutic failures since CSII failed to induce euglycemia (n = 1) or glucose control deteriorated within 6 months after CSII (n = 3). The remaining nine patients were maintained on diet alone with adequate control from 9 to > 50 months (median +/- SE, 26 +/- 4.8 months). In five patients, glycemic control deteriorated after 9-36 months, but a repeat 2-week CSII treatment reestablished control in four patients. One of these patients underwent a third CSII treatment 13 months later. At the time this article was written, six patients of the initial group were still controlled without medication 16-59 months (median +/- SE, 45.5 +/- 6.6 months) after the initiation of treatment. Body weight remained unchanged in all patients.
conclusionsThese findings suggest that in a significant proportion of type 2 diabetic patients who fail to respond to dietary measures, short-term intensive insulin treatment can effectively establish responsiveness, allowing long-term glycemic control without medication. Further studies are required to establish whether simpler treatment regimens could be equally effective. If the hypothesis offered here finds support, present approaches to the management of newly diagnosed type 2 diabetes may need to be revised.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.